

Table 1.6
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
By Primary Cancer Site, Sex and Time Period

Site	Blacks											
	Incidence ^a (2013-2017)			US Mortality ^b (2013-2017)			Survival ^c (%) (2010-2016)					
	Total	Males	Females	Total	Males	Females	Total	Males	Females			
All Sites	440.4	515.1	390.7	181.7	227.3	153.4	62.5	64.4	60.6			
Oral Cavity & Pharynx:	8.5	13.3	4.9	2.7	4.5	1.3	49.5	47.6	53.8			
Lip	0.1	0.1	0.0	-	-	-	72.0	63.8	-			
Tongue	1.9	3.2	1.0	0.5	0.8	0.3	46.4	47.1	44.6			
Salivary gland	1.1	1.1	1.1	0.2	0.3	0.2	74.3	68.6	78.9			
Floor of mouth	0.4	0.7	0.2	0.0	0.1	-	40.2	40.1	39.1			
Gum & other oral cavity	1.2	1.5	1.0	0.3	0.5	0.2	53.7	48.7	58.9			
Nasopharynx	0.7	1.0	0.3	0.2	0.4	0.1	52.1	53.8	48.9			
Tonsil	1.6	2.9	0.6	0.2	0.4	0.1	58.9	59.5	56.0			
Oropharynx	0.6	1.0	0.3	0.4	0.6	0.2	31.7	31.1	32.4			
Hypopharynx	0.8	1.4	0.3	0.2	0.3	0.0	21.3	21.1	21.7			
Other oral cavity & pharynx	0.2	0.4	0.1	0.6	1.1	0.2	30.8	29.0	35.4			
Digestive System:	94.7	117.4	78.2	51.7	67.5	40.2	40.5	37.0	44.3			
Esophagus	3.7	6.1	2.0	3.2	5.3	1.6	14.0	12.2	17.7			
Stomach	10.1	13.8	7.6	5.3	7.8	3.6	31.9	26.1	39.4			
Small intestine	3.8	4.4	3.4	0.6	0.8	0.6	65.8	66.6	65.0			
Colon & Rectum:	43.6	51.3	38.2	18.5	23.2	15.2	58.8	56.8	60.6			
Colon	32.0	36.5	28.8	-	-	-	57.0	56.2	57.7			
Rectum	11.6	14.8	9.3	-	-	-	63.4	58.3	69.4			
Anus, anal canal & anorectum	2.1	2.2	1.9	0.3	0.3	0.2	62.3	57.7	66.7			
Liver & intrahepatic	10.7	17.7	5.4	8.4	13.2	4.8	17.1	15.9	20.5			
bile duct	1.8	1.4	2.2	0.9	0.7	1.0	16.3	15.5	16.5			
Gallbladder	1.8	2.1	1.6	0.4	0.5	0.4	17.1	14.9	19.0			
Other biliary	15.3	16.9	14.1	13.3	14.9	12.0	10.1	9.2	10.8			
Pancreas	0.4	0.3	0.4	0.1	0.1	0.1	54.9	56.5	53.6			
Retroperitoneum	0.4	0.1	0.5	0.2	0.1	0.3	34.3	39.9	33.7			
Peritoneum, omentum &												
mesentery												
Other digestive system	0.9	1.0	0.8	0.5	0.6	0.4	7.8	6.2	9.3			
Respiratory System:	59.5	79.6	45.8	44.1	62.3	31.8	21.4	19.6	23.6			
Nose, nasal cavity &	0.6	0.8	0.5	0.1	0.2	0.1	55.2	54.0	57.1			
middle ear												
Larynx	3.9	7.3	1.4	1.6	3.0	0.5	51.7	52.6	48.7			
Lung & bronchus	54.8	71.2	43.8	42.3	58.8	31.1	18.4	15.1	22.3			
Pleura ^d	-	-	-	0.0	0.1	0.0	-	-	-			
Trachea & other	0.2	0.2	0.1	0.1	0.1	0.0	49.9	47.2	55.3			
respiratory organs												
Bones & joints	0.8	0.9	0.7	0.5	0.6	0.4	63.1	64.4	61.6			
Soft tissue (including heart)	3.4	3.8	3.1	1.5	1.5	1.5	61.1	60.9	61.3			
Skin (excl. basal & squamous):	2.1	2.3	2.0	0.8	1.1	0.5	82.2	77.8	85.5			
Melanoma of the skin	1.0	1.1	0.9	0.3	0.4	0.3	66.7	59.5	72.1			
Other non-epithelial skin	1.1	1.2	1.1	0.4	0.7	0.2	93.5	90.4	96.0			
Breast	71.3	1.8	124.8	16.2	0.5	27.6	81.9	73.9	82.0			
Breast (in situ)	18.6	0.2	33.0	-	-	-	100.0	95.2	100.0			

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 18 areas. Based on follow-up of patients into 2017. Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^d Mesotheliomas of the Pleura are included in the separate group Mesothelioma for incidence but are included in the Pleura grouping for mortality.

- Statistic could not be calculated due to less than 16 cases in the time interval.

Table 1.6 - continued
Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival (Percent)
By Primary Cancer Site, Sex and Time Period

Site	Blacks											
	Incidence ^a (2013-2017)			US Mortality ^b (2013-2017)			Survival ^c (%) (2010-2016)					
	Total	Males	Females	Total	Males	Females	Total	Males	Females			
Female Genital System:	28.2	-	49.8	11.0	-	18.9	56.9	-	56.9			
Cervix uteri	4.8	-	8.7	1.9	-	3.4	55.6	-	55.6			
Corpus uteri	14.9	-	26.2	2.1	-	3.6	65.1	-	65.1			
Uterus, NOS	1.0	-	1.7	2.9	-	4.9	23.5	-	23.5			
Ovary ^d	5.2	-	9.1	3.5	-	6.0	40.8	-	40.8			
Vagina	0.5	-	0.9	0.2	-	0.3	44.3	-	44.3			
Vulva	1.0	-	1.8	0.2	-	0.3	71.5	-	71.5			
Other female genital system	0.8	-	1.3	0.2	-	0.3	52.3	-	52.3			
Male Genital System:	75.7	178.2	-	14.2	38.3	-	96.0	96.0	-			
Prostate	74.4	175.2	-	14.0	37.9	-	96.2	96.2	-			
Testis	0.8	1.7	-	0.1	0.1	-	92.3	92.3	-			
Penis	0.4	1.0	-	0.1	0.2	-	58.4	58.4	-			
Other male genital system	0.1	0.3	-	0.0	0.1	-	68.7	68.7	-			
Urinary System:	29.9	45.1	19.2	7.2	11.0	4.8	71.0	72.0	69.6			
Urinary bladder	11.8	19.7	6.5	3.5	5.3	2.4	63.9	68.4	55.2			
Kidney & renal pelvis	17.5	24.5	12.2	3.6	5.4	2.2	75.8	74.8	77.3			
Ureter	0.2	0.3	0.2	0.0	0.0	0.0	28.8	21.1	33.2			
Other urinary system	0.5	0.6	0.4	0.1	0.2	0.1	41.9	44.2	37.2			
Eye & Orbit	0.3	0.3	0.3	0.0	0.0	0.0	88.1	85.4	90.1			
Brain & Nervous System: ^e	3.9	4.5	3.3	2.6	3.2	2.2	38.9	37.2	40.7			
Brain	3.5	4.2	3.0	-	-	-	35.0	33.6	36.5			
Cranial nerves & other nervous system	0.3	0.4	0.3	-	-	-	77.0	77.0	76.4			
Endocrine System:	10.5	5.0	15.2	0.9	0.8	0.9	94.3	87.2	96.1			
Thyroid	9.5	4.0	14.3	0.5	0.4	0.6	97.2	92.8	97.9			
Other endocrine & thymus	1.0	1.0	0.9	0.4	0.4	0.3	67.0	67.2	66.7			
Lymphoma:	17.4	20.7	14.8	4.3	5.5	3.4	71.6	69.4	74.3			
Hodgkin lymphoma	2.7	3.1	2.3	0.3	0.3	0.2	85.4	83.3	87.7			
Non-Hodgkin lymphoma	14.7	17.7	12.5	4.0	5.2	3.2	68.4	66.0	71.2			
Myeloma	13.8	16.5	12.0	6.2	7.5	5.3	56.8	56.3	57.3			
Leukemia:	10.8	13.6	8.9	5.4	7.0	4.3	58.9	62.4	55.0			
Lymphocytic:	4.5	6.1	3.4	1.4	1.9	1.1	75.4	78.6	71.2			
Acute lymphocytic	1.0	1.1	0.9	0.3	0.4	0.3	65.2	66.4	63.6			
Chronic lymphocytic	3.3	4.8	2.4	1.0	1.5	0.7	79.7	83.0	75.2			
Other lymphocytic	0.2	0.3	0.1	0.1	0.1	0.1	69.0	73.5	55.0			
Myeloid & Monocytic:	5.7	6.9	5.0	2.7	3.4	2.2	44.5	45.7	43.3			
Acute myeloid	3.7	4.4	3.3	2.2	2.7	1.9	28.6	27.7	29.5			
Chronic myeloid	1.8	2.2	1.5	0.3	0.4	0.2	71.6	72.7	70.2			
Acute monocytic	0.1	0.2	0.1	0.0	0.0	-	24.3	29.1	21.0			
Other myeloid & monocytic	0.1	0.2	0.1	0.2	0.3	0.1	38.3	42.0	31.2			
Other leukemia:	0.6	0.6	0.6	1.3	1.7	1.0	41.6	45.1	37.2			
Other acute leukemia	0.2	0.2	0.2	0.3	0.4	0.3	29.3	26.4	34.3			
Aleurkemic, subleukemic & NOS	0.4	0.4	0.4	1.0	1.2	0.8	48.0	55.9	39.3			
Kaposi Sarcoma ^f	1.0	2.0	0.2	-	-	-	64.9	66.7	35.5			
Mesothelioma ^f	0.5	0.9	0.2	-	-	-	15.3	10.9	22.1			
Ill-defined & unspecified	8.1	9.3	7.3	12.6	16.1	10.3	12.9	13.1	13.0			

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 US Std Population (19 age groups - Census P25-1130).

^a SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

^b US Mortality Files, National Center for Health Statistics, Centers for Disease Control and Prevention.

^c SEER 18 areas. Based on follow-up of patients into 2017. Expected survival rates are derived from life tables by socio-economic status, geography and race developed by the SEER program.

^d Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

^e Due to coding changes, Brain & Nervous System mortality are no longer shown separately.

^f Rate not shown for mortality. Category did not exist in mortality coding until 1999.

- Statistic could not be calculated due to less than 16 cases in the time interval.